相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression
Andrea Nemecek et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Erin E. Longbrake et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression
Andrea Nemecek et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Erin E. Longbrake et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS Patient management considerations
Robert J. Fox et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
Steven K. Lundy et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
Catharina C. Gross et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
L. Kappos et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers
Christopher M. Gidicsin et al.
NEUROLOGY (2015)
PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
Dennis J. Nieuwkamp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Thorsten Rosenkranz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dimethyl fumarate associated lymphopenia in clinical practice
Erin E. Longbrake et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
Collin M. Spencer et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Glial cells express nuclear Nrf2 after fumarate treatment for multiple sclerosis and psoriasis (vol 2, e99, 2015)
I. Metz
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
PML in a Patient Treated with Fumaric Acid
Ummehan Ermis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Case Reports of PML in Patients Treated for Psoriasis
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Robert H. Scannevin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration
S. Schilling et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Oral fumaric acid esters for the treatment of active multiple sclerosis:: an open-label, baseline-controlled pilot study
S. Schimrigk et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Dimethylfumarate is a potent inducer of apoptosis in human T cells
F Treumer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
分享论文
